Vizsgálati helyszín
Centrum Medyczne HCP Sp. z o.o.
Poznan, Greater Poland Voivodeship 61-485, LengyelországEU-13 felzárkózó országMég nincs intézményhez kötve
- 21futó vizsgálat
- 5lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 26 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis15 vizsgálat
- 2. fázis9 vizsgálat
- 2/3. fázis2 vizsgálat
- Állapot
- Toboroz15 vizsgálat
- Lezárult4 vizsgálat
- Fut, nem toboroz3 vizsgálat
- Még nem toboroz3 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- Bristol-Myers Squibb4 vizsgálat
- Emalex Biosciences Inc.2 vizsgálat
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company2 vizsgálat
- MapLight Therapeutics2 vizsgálat
- Zenas BioPharma (USA), LLC2 vizsgálat
- és még 14
Futó vizsgálatok
Meghívásos bevonás
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
NCT07459660· 2. fázis· MapLight Therapeutics· Forrás
Toboroz
DT-101 in Adults with Major Depressive Disorder
2025-522784-15-00· 2. fázis· Draig Therapeutics Limited· Forrás
Toboroz
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019· 3. fázis· Zenas BioPharma (USA), LLC· Forrás
Toboroz
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463· 3. fázis· Zenas BioPharma (USA), LLC· Forrás
Toboroz
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
NCT07288333· 2. fázis· Neurocrine Biosciences· Forrás
Toboroz
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
NCT07284472· 2/3. fázis· Exciva GmbH· Forrás
Toboroz
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751· 3. fázis· BioNTech SE· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
NCT06887192· 2. fázis· MapLight Therapeutics· Forrás
Toboroz
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
NCT06976268· 2/3. fázis· Biohaven Therapeutics Ltd.· Forrás
Toboroz
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
NCT06929806· 3. fázis· Pharmacosmos A/S· Forrás
Fut, nem toboroz
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
NCT06602479· 2. fázis· AbbVie· Forrás
Toboroz
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Toboroz
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.
2022-501622-37-00· 3. fázis· Celltrion Inc.· Forrás
Fut, nem toboroz
A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
NCT06021522· 3. fázis· Emalex Biosciences Inc.· Forrás
Toboroz
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Toboroz
A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLUTION study)
2023-507372-42-00· 2. fázis· Oryzon Genomics S.A.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek